ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM... ( PARIS March 16 /- ExonHit Therape...)

ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform

Date:3/16/2009

PARIS, March 16 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) today reported the publication in Lancet Oncology of a study conducted by Institut Gustave Roussy, which describes the identification of a deregulated cell function in breast cancer through the analysis of alternative RNA splicing [1]. Study data demonstrate that exons are differently expressed in malignant and benign lesions, and alternative transcripts determine the molecular characteristics of breast malignancy.

"The splice variants that we have identified could be used as targets for development of targeted therapies and also for a more precise diagnostic test. A molecular diagnosis for breast cancer could improve the performance of current diagnosis methods by increasing accuracy of cytological investigations and decreasing the use of core-needle biopsy or exploratory surgery," said Fabrice Andre, M.D. Breast Cancer Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. He added: "Patients could greatly benefit from a more precise diagnosis."

"We are very happy to report that this independent study demonstrates the clinical usefulness of our SpliceArray(TM) platform. It constitutes another example of its many possible applications," stated Dr. Loic Maurel, President of the Management Board of ExonHit Therapeutics. "We are using the same technology platform for all our blood based diagnostic projects; our internally funded diagnostic test for Alzheimer's disease (EHT Dx21) and the breast, colon and prostate cancer diagnostics developed with bioMerieux. We look forward to seeing other applications of our technology and launching the first product developed with this technology on the market."

SpliceArray(TM) biochips are ExonHit's proprietary research tools [2]. They quantify mRNA expression at the exon level. They also provide a comprehensive RNA splicing analysis across the entir
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
2. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
3. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
4. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
5. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
6. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
7. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
8. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
9. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
10. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
11. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist

Post Your Comments:

ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM...( PARIS March 16 /- ExonHit Therape...),Health